FORMULATION AND IN VIVO EVALUATION OF PEMIGATINIB SUPER SATURABLE SELF-NANO EMULSIFYING DRUG DELIVERY SYSTEM

MUTHADI RADHIKA REDDY; SHIVA KUMAR GUBBIYAPPA

doi:10.22159/ijap.2023v15i6.48981

Authors

MUTHADI RADHIKA REDDY Department of Pharmaceutics, Gitam School of Pharmacy, GITAM Deemed to be University, Hyderabad-502329, Telangana, India https://orcid.org/0000-0001-8205-4915
SHIVA KUMAR GUBBIYAPPA Department of Pharmaceutics, Gitam School of Pharmacy, GITAM Deemed to be University, Hyderabad-502329, Telangana, India https://orcid.org/0000-0002-9075-6535

DOI:

https://doi.org/10.22159/ijap.2023v15i6.48981

Keywords:

Pemigatinib, Cholangiocarcinoma, Solubility, sSNEDDS, Pharmacokinetics

Abstract

Objective: Pemigatinib is an active component in treatment of cholangiocarcinoma, but the low solubility and bioavailability of Pemigatinib limit its wide application. The aim of the present study was to prepare and evaluate supersaturable self-nanoemulsifying drug delivery systems (sSNEDDS) followed by investigating and comparing the pharmacokinetic profiles of Pemigatinib and Pemigatinib sSNEDDS in rat plasma by HPLC.

Methods: Pemigatinib loaded SNEDDS were obtained by dissolving drug in the isotropic mixture of oil, surfactant, and co-surfactant. The conventional SNEDDS were converted to sSNEDDS by precipitation method by using an experimented polymer. An appropriate high sensitivity and selectivity was applied to the comparison of plasma pharmacokinetics in Pemigatinib and Pemigatinib sSNEDDS using Entrectinib as an internal standard (IS).

Results: The droplet of sSNEDDS ranges from 166.78±3.14 to 178.86±1.24 nm with PDI 0.212–0.256, transmission electron microscopy images revealed the spherical shape of the nanodroplets, emulsification time was 15 secs when added to physiological fluids, percent transmittance of the diluted formulation was 99.12±0.46, and viscosity was 574±26 centipoises indicating the good flow ability. FTIR and DSC studies indicated the amorphization of the drug. The dissolution profile of sSNEDDS indicated the faster release of drug compared to both pure drug suspension and SNEDDS formulation. C_max of the sSNEDDS 3.52±0.13ng/ml was significant (P<0.05) as compared to the pure drug suspension formulation 2.82±0.42 ng/ml. The AUC_0-t, AUC_0–∞of sSNEDDS was increased, while the T_max and t_1/2 was decreased. Moreover, the AUC value in the sSNEDDS group was significantly increased and the relative bioavailability was calculated to be 69% when compared with that of the Pemigatinib group.

Conclusion: These results concluded that Pemigatinib sSNEDDS when compared with pure drug after a single oral administration and the formulation modification of Pemigatinib into sSNEDDS can effectively enhance gastrointestinal absorption and relative bioavailability by improving solubility and dissolution rate.

Downloads

Download data is not yet available.

References

Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut. 2012 Dec;61(12):1657-69. doi: 10.1136/gutjnl-2011-301748, PMID 22895392.

Yamamoto M, Takasaki K, Otsubo T, Katsuragawa H, Katagiri S. Recurrence after surgical resection of intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Surg. 2001 Feb;8(2):154-7. doi: 10.1007/s005340170039, PMID 11455472.

Hoy SM. Pemigatinib: first approval. Drugs. 2020 Jun;80(9):923-9. doi: 10.1007/s40265-020-01330-y, PMID 32472305.

Wu L, Zhang C, He C, Qian D, Lu L, Sun Y. Discovery of pemigatinib: a potent and selective fibroblast growth factor receptor (FGFR) inhibitor. J Med Chem. 2021 Aug;64(15):10666-79. doi: 10.1021/acs.jmedchem.1c00713, PMID 34269576.

Annisa R, Mutiah R, Yuwono M, Hendradi E. Nanotechnology approach-self nanoemulsifying drug delivery system (SNEDDS). Int J App Pharm. 2023 Jul;15(4):12-9. doi: 10.22159/ijap.2023v15i4.47644.

Madhavi K, Shikha A, Suresh B. Formulation and in vitro characterization solid self-emulsifying drug delivery system of ramipril prepared by adsorption technique. Int J Curr Pharm Res. 2016 Jan;8(1):40-5.

Jayapal N, Vamshi Vishnu Y. Formulation and in vivo evaluation of self-nanoemulsifying drug delivery system of ramipril in Wistar rats. Asian J Pharm Clin Res. 2021 Jul;14(7):126-36. doi: 10.22159/ajpcr.2021.v14i7.42003.

Buya AB, Beloqui A, Memvanga PB, Preat V. Self-nano-emulsifying drug-delivery systems: from the development to the current applications and challenges in oral drug delivery. Pharmaceutics. 2020 Dec;12(12):1194. doi: 10.3390/pharmaceutics12121194, PMID 33317067.

Thomas N, Mullertz A, Graf A, Rades T. Influence of lipid composition and drug load on the in vitro performance of self-nanoemulsifying drug delivery systems. J Pharm Sci. 2012 May;101(5):1721-31. doi: 10.1002/jps.23054, PMID 22294458.

Chiu YY, Higaki K, Neudeck BL, Barnett JL, Welage LS, Amidon GL. Human jejunal permeability of cyclosporin a: influence of surfactants on P-glycoprotein efflux in Caco-2 cells. Pharm Res. 2003 May;20(5):749-56. doi: 10.1023/a:1023481418576, PMID 12751630.

Thomas N, Holm R, Mullertz A, Rades T. In vitro and in vivo performance of novel supersaturated self-nanoemulsifying drug delivery systems (super-SNEDDS). J Control Release. 2012 May;160(1):25-32. doi: 10.1016/j.jconrel.2012.02.027, PMID 22405903.

Thomas N, Mullertz A, Graf A, Rades T. Influence of lipid composition and drug load on the in vitro performance of self-nanoemulsifying drug delivery systems. J Pharm Sci. 2012 May;101(5):1721-31. doi: 10.1002/jps.23054, PMID 22294458.

Yoshinari K, Yamashita K. Analytical chemistry for ADMET research: recent advances and future directions in LC-MS/MS and omics approaches. Drug Metab Pharmacokinet. 2016 Feb;31(1):1-2. doi: 10.1016/j.dmpk.2015.12.006, PMID 26852145.

Hou S, Wang F, Li Y, Li Y, Wang M, Sun D. Pharmacokinetic study of mangiferin in human plasma after oral administration. Food Chem. 2012 May;132(1):289-94. doi: 10.1016/j.foodchem.2011.10.079, PMID 26434292.

Liu Y, Huang J, Liu J, Ma L, Lv Y, Shi S. A simple and sensitive liquid chromatographic technique for the determination of cefotetan disodium in human plasma and its application in a pharmacokinetic study. J Huazhong Univ Sci Technolog Med Sci. 2012 Oct;32(5):779-84. doi: 10.1007/s11596-012-1034-2, PMID 23073813.

Zhang J, Peng Q, Shi S, Zhang Q, Sun X, Gong T. Preparation, characterization, and in vivo evaluation of a self-nanoemulsifying drug delivery system (SNEDDS) loaded with morin-phospholipid complex. Int J Nanomedicine. 2011 Jun;6:3405-14. doi: 10.2147/IJN.S25824, PMID 22267925.

Schmied FP, Bernhardt A, Engel A, Klein S. A customized screening tool approach for the development of a self-nanoemulsifying drug delivery system (SNEDDS). AAPS PharmSciTech. 2021 Dec;23(1):39. doi: 10.1208/s12249-021-02176-7, PMID 34961897.

Nasr A, Gardouh A, Ghorab M. Novel solid self-nanoemulsifying drug delivery system (S-SNEDDS) for oral delivery of olmesartan medoxomil: design, formulation, pharmacokinetic and bioavailability evaluation. Pharmaceutics. 2016 Jun;8(3):20. doi: 10.3390/pharmaceutics8030020, PMID 27355963.

Zafar A, Yasir M, Alruwaili NK, Imam SS, Alsaidan OA, Alshehri S. Formulation of self-nanoemulsifying drug delivery system of cephalexin: physiochemical characterization and antibacterial evaluation. Polymers (Basel). 2022 Mar;14(5):1055. doi: 10.3390/polym14051055, PMID 35267877.

Ilie AR, Griffin BT, Vertzoni M, Kuentz M, Kolakovic R, Prudic Paus A. Exploring precipitation inhibitors to improve in vivo absorption of cinnarizine from supersaturated lipid-based drug delivery systems. Eur J Pharm Sci. 2021 Apr;159:105691. doi: 10.1016/j.ejps.2020.105691, PMID 33359616.

Subramanian P, Rajnikanth PS, Kumar M, Chidambram K. In vitro and in vivo evaluation of supersaturable self-nanoemulsifying drug delivery system (SNEDDS) of dutasteride. Curr Drug Deliv. 2020 Jan;17(1):74-86. doi: 10.2174/1567201816666191112111610, PMID 31721703.

Shen C, Pan Z, Wu X, Zhong C, Li Q, Si Y. A sensitive liquid chromatography-mass spectrometry method for determination of toosendanin in rat plasma and its application to pharmacokinetic study. J Chromatogr Sci. 2022 Jun;60(5):478-85. doi: 10.1093/chromsci/bmab135, PMID 34929736.

Wang L, Phan DK, Syn N, Xiang X, Song H, Thuya WL. A sensitive liquid chromatography-tandem mass spectrometry method for the determination of nimbolide in mouse serum: application to a preclinical pharmacokinetics study. Pharmaceutics. 2018 Aug;10(3):123. doi: 10.3390/pharmaceutics10030123, PMID 30096831.

Jaiswal R, Wadetwar R. Development and validation of the RP-HPLC method for estimation of cilnidipine in rat plasma. Int J Pharm Pharm Sci. 2022 Oct;14(10):32-7. doi: 10.22159/ijpps.2022v14i10.45940.

Balap AR. To study the pharmacokinetic herb-drug interaction of Momordica Charantia fruit extract and pure charantin with nateglinide in rats. Int J Pharm Pharm Sci. 2021 Sep;13(9):1-5.

Zheng B, Chen D, Yang X, Igo LP, Li Z, Ye X. Development and validation of an UPLC-PDA method for the determination of corilagin in rat plasma and its application to pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Sep;1031:76-9. doi: 10.1016/j.jchromb.2016.07.039, PMID 27459126.

Alagar R, Ashwini David B, Rao KN, Selva K. A new analytical method development and validation for the estimation of olmesartanmedoxomil and cilnidipine in its pharmaceutical dosage form by UPLC as per ICH guidelines d2. Asian J Rese Bio Pharm Sci. 2015 Feb;3(2):78-86.

Amit SM, Manjusha ND, Sanjay DS. Development and validation of an analytical method for simultaneous estimation of cilnidipine and olmesartanmedoxomil in bulk and tablet dosage form by RP-HPLC. Int J Pharm Pharm Sci. 2014 Jun;7(6):508-11.

Gao Y, Liu YZ, Zhang XM, Zhou Y, Zhang X, Dong CY. Pharmacokinetic studies of bergapten in dog plasma by using LC-MS/MS method studies. Drug Res (Stuttg). 2013 Jul;63(7):338-41. doi: 10.1055/s-0033-1341426, PMID 23549759.

Lv G, Lou Z, Chen S, Gu H, Shan L. Pharmacokinetics and tissue distribution of 2,3,5,4'-tetrahydroxystilbene-2-O-β-D-glucoside from traditional Chinese medicine Polygonum multiflorum following oral administration to rats. J Ethnopharmacol. 2011 Sep;137(1):449-56. doi: 10.1016/j.jep.2011.05.049, PMID 21679759.

Maiti K, Mukherjee K, Gantait A, Saha BP, Mukherjee PK. Curcumin-phospholipid complex: preparation, therapeutic evaluation and pharmacokinetic study in rats. Int J Pharm. 2007 Feb;330(1-2):155-63. doi: 10.1016/j.ijpharm. 2006.09.025, PMID 17112692.

Ji T, Chen X, Yeleswaram S. Evaluation of drug-drug interaction potential for pemigatinib using physiologically based pharmacokinetic modeling. CPT Pharmacometrics Syst Pharmacol. 2022 Jul;11(7):894-905. doi: 10.1002/psp4.12805, PMID 35506332.

Subbiah V, Iannotti NO, Gutierrez M, Smith DC, Feliz L, Lihou CF. FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies. Ann Oncol. 2022 May;33(5):522-33. doi: 10.1016/j.annonc.2022.02.001, PMID 35176457.

Ji T, Rockich K, Epstein N, Overholt H, Wang P, Chen X. Evaluation of the pharmacokinetics of pemigatinib in patients with impaired hepatic or renal function. Br J Clin Pharmacol. 2022 Jan;88(1):237-47. doi: 10.1111/bcp.14954, PMID 34169560.